OMER · Omeros Corporation
$9.79
-0.53% last session
End-of-day data · updated 2026-07-28
Market cap
$1B
Enterprise value
$1B
Trailing P/E
10.0
Forward P/E
29.8
Dividend yield
—
Beta
2.55
Avg volume
2M
Employees
0K
2D change
—
5D change
10.31%
10D change
17.03%
30D change
30.80%
60D change
2.72%
MTD change
20.51%
YTD change
-33.99%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — OMER
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-06-26
Latest call per bank · past 12 months
Recent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-06-26 | HC Wainwright & Co. | Maintains | Buy | $40.00 → $33.00 |
| 2026-06-10 | HC Wainwright & Co. | Reiterates | Buy | $40.00 |
| 2026-05-14 | HC Wainwright & Co. | Reiterates | Buy | $40.00 |
| 2026-04-21 | D. Boral Capital | Maintains | Buy | $36.00 |
| 2026-01-27 | D. Boral Capital | Maintains | Buy | $36.00 |
| 2026-01-08 | HC Wainwright & Co. | Maintains | Buy | $20.00 → $40.00 |
| 2026-01-08 | D. Boral Capital | Maintains | Buy | $36.00 |
| 2025-12-24 | D. Boral Capital | Maintains | Buy | $36.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 59 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 9.0% above the 50-day MA ($10.35).
- Price vs 200-day MA: Trading 3.9% above the 200-day MA ($10.86).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is positive (+0.19) — short-term momentum is improving.
- 52-week range: Price sits between the 52-week low ($3.61) and high ($17.18).
OMER Price Chart
Loading chart for OMER…
Fundamentals
About Omeros Corporation
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$122B 5.7% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$70B -13.3% YTD
ARGX
argenx SE
$56B 5.7% YTD
RVMD
Revolution Medicines, Inc.
$40B 136.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$37B -30.0% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.5% YTD
ROIV
Roivant Sciences Ltd.
$25B 60.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.